CY1117869T1 - Φαρμακοτεχνικες μορφες για απο του στοματος απελευθερωση προσροφητικων στο εντερο - Google Patents

Φαρμακοτεχνικες μορφες για απο του στοματος απελευθερωση προσροφητικων στο εντερο

Info

Publication number
CY1117869T1
CY1117869T1 CY20161100748T CY161100748T CY1117869T1 CY 1117869 T1 CY1117869 T1 CY 1117869T1 CY 20161100748 T CY20161100748 T CY 20161100748T CY 161100748 T CY161100748 T CY 161100748T CY 1117869 T1 CY1117869 T1 CY 1117869T1
Authority
CY
Cyprus
Prior art keywords
formulation
pharmaceutical forms
intestine
oral release
adsorbent
Prior art date
Application number
CY20161100748T
Other languages
English (en)
Inventor
François Lescure
Gunzburg Jean De
Original Assignee
Da Volterra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Da Volterra filed Critical Da Volterra
Publication of CY1117869T1 publication Critical patent/CY1117869T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731—Carrageenans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Η εφεύρεση αφορά σε μια φαρμακοτεχνικη μορφή για την καθυστερημένη και ελεγχόμενη απελευθέρωση ενός προσροφητικού εντός του κατώτερου εντέρου θηλαστικών. Η φαρμακοτεχνικη μορφή περιλαμβάνει καραγενάνη και ένα προσροφητικό, όπως ενεργό άνθρακα. Η εφεύρεση περαιτέρω αφορά στις χρήσεις αυτής της φαρμακοτεχνικής μορφής, ιδιαιτέρως σε φαρμακευτικές χρήσεις. Σε μια πραγματοποίηση, η φαρμακοτεχνική μορφή χρησιμοποιείται για την εξάλειψη ή μείωση των παρενεργειών στο έντερο, ιδιαιτέρως στο κόλον, φαρμακευτικών παραγόντων που χορηγούνται ως θεραπεία για μια διαταραχή, αλλά που έχουν παρενέργειες όταν αυτοί φτάσουν στο τελικό τμήμα του ειλεού, στο τυφλό έντερο ή στο κόλον.
CY20161100748T 2010-02-23 2016-07-29 Φαρμακοτεχνικες μορφες για απο του στοματος απελευθερωση προσροφητικων στο εντερο CY1117869T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10305179 2010-02-23
EP11704468.5A EP2538930B1 (en) 2010-02-23 2011-02-23 Formulations for oral delivery of adsorbents in the gut
PCT/EP2011/052682 WO2011104275A1 (en) 2010-02-23 2011-02-23 Formulations for oral delivery of adsorbents in the gut

Publications (1)

Publication Number Publication Date
CY1117869T1 true CY1117869T1 (el) 2017-05-17

Family

ID=42357439

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100748T CY1117869T1 (el) 2010-02-23 2016-07-29 Φαρμακοτεχνικες μορφες για απο του στοματος απελευθερωση προσροφητικων στο εντερο

Country Status (23)

Country Link
US (4) US9968562B2 (el)
EP (1) EP2538930B1 (el)
JP (1) JP5645975B2 (el)
KR (1) KR101820374B1 (el)
CN (1) CN102869351B (el)
AU (1) AU2011219788B2 (el)
BR (1) BR112012021275B1 (el)
CA (1) CA2790811C (el)
CY (1) CY1117869T1 (el)
ES (1) ES2586135T3 (el)
HK (1) HK1180233A1 (el)
HR (1) HRP20160834T1 (el)
HU (1) HUE029299T2 (el)
IL (1) IL221542A (el)
LT (1) LT2538930T (el)
MX (1) MX340822B (el)
PL (1) PL2538930T3 (el)
PT (1) PT2538930T (el)
RS (1) RS54991B1 (el)
RU (2) RU2012140421A (el)
SI (1) SI2538930T1 (el)
WO (1) WO2011104275A1 (el)
ZA (1) ZA201207068B (el)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2538930T (pt) * 2010-02-23 2016-08-05 Da Volterra Formulações para administração oral de adsorventes no intestino
MX338535B (es) 2010-11-08 2016-04-21 Albireo Ab Inhibidores de ibat para el tratamiento de enfermeades hepaticas.
CN102432737B (zh) * 2011-09-07 2015-02-25 张绍国 一种缓释肠溶丙烯酸树脂乳胶液及其制法
GB201204696D0 (en) 2012-03-16 2012-05-02 Ucl Business Plc Therapy
DK2897594T3 (da) 2012-09-21 2020-06-29 Ferring Bv Farmaceutisk sammensætning
US9907755B2 (en) * 2013-03-14 2018-03-06 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
WO2014154677A1 (en) * 2013-03-25 2014-10-02 Ferring Bv Composition for the treatment of disease
KR20220082931A (ko) 2014-06-25 2022-06-17 이에이 파마 가부시키가이샤 고형 제제 및 그의 착색 방지 또는 착색 감소 방법
WO2017060178A1 (en) * 2015-10-06 2017-04-13 Da Volterra Suppression or reduction of the pathogenicity or virulence of a clostridium bacteria
KR20180070591A (ko) * 2015-10-26 2018-06-26 다이이찌 산쿄 가부시키가이샤 다공질 재료의 대장 또는 소장 하부에 대한 딜리버리 제제
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
CN108601745B (zh) * 2016-02-09 2021-12-07 阿尔比里奥公司 口服考来烯胺制剂及其用途
US10786529B2 (en) * 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
KR101884520B1 (ko) * 2016-07-29 2018-08-02 한국식품연구원 벤토나이트를 유효성분으로 포함하는 염증성 장 질환의 예방 또는 치료용 약학적 조성물
KR102106477B1 (ko) * 2017-01-12 2020-05-06 차장옥 콕시듐증 예방 또는 치료용 조성물, 이의 제조방법 및 이의 이용
CA3071285A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine granules, oral cholestyramine formulations and use thereof
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
AU2019290337B2 (en) 2018-06-20 2023-01-12 Albireo Ab Crystal modifications of odevixibat
CA3106433A1 (en) 2018-08-05 2020-02-13 Da Volterra Compositions for the treatment of graft versus host disease
MX2021001394A (es) 2018-08-05 2021-04-12 Da Volterra Metodo para mejorar la eficacia de un agente anticanceroso.
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
EP4125847A1 (en) 2020-04-03 2023-02-08 Lpoxy Therapeutics, Inc. Enteric aerobization therapy
RU2747401C1 (ru) * 2020-06-22 2021-05-04 Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный университет" Способ получения фармацевтических лекарственных форм на основе сополимеров метилметакрилата
WO2022084550A1 (en) 2020-10-23 2022-04-28 Da Volterra Compositions for use in the treatment or prevention of dysbiosis
WO2022090433A1 (en) 2020-10-30 2022-05-05 Da Volterra Method for the manufacture of an adsorbent formulation
WO2022101267A2 (en) 2020-11-12 2022-05-19 Da Volterra Compositions for delivery of an adsorbent
WO2022101269A1 (en) 2020-11-13 2022-05-19 Da Volterra Formulations and dosage regimen for oral delivery of adsorbents in the gut

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3917821A (en) 1973-10-23 1975-11-04 Milton Manes Palatable activated carbon
US4761284A (en) * 1977-12-27 1988-08-02 Kureha Kagaku Kogy Kabushiki Kaisha Antidote including activated carbon particles
JPS5542210A (en) * 1978-09-12 1980-03-25 Koichi Ogawa Special activated carbon
JPS62168540A (ja) * 1986-01-21 1987-07-24 Freunt Ind Co Ltd 被覆方法
US5597564A (en) * 1986-08-28 1997-01-28 Enzacor Properties Limited Method of administering a microgranular preparation to the intestinal region of animals
EP0321481B1 (en) 1986-08-28 1994-06-01 Enzacor Properties Limited Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals
US5356625A (en) 1986-08-28 1994-10-18 Enzacor Properties Limited Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals
GB8812490D0 (en) 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
JPH03120227A (ja) 1989-10-02 1991-05-22 Shigeo Ochi 飲食物消化分解産物吸収抑制剤
IT1246382B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
JP3338119B2 (ja) * 1993-04-14 2002-10-28 呉羽化学工業株式会社 抗糖尿病剤
US5827497A (en) 1996-08-14 1998-10-27 Mayo Foundation For Medical Education And Research Charcoal-radionuclide agents for measurement of gastrointestinal transit
FR2780052B1 (fr) 1998-06-23 2000-07-21 Ceca Sa Agglomerats a base de charbon actif leur procede de preparation et leur utilisation comme agents d'adsorption
JP2004507339A (ja) 2000-04-21 2004-03-11 ウォーターヴィジョンズ　インターナショナル，　インコーポレイティッド 膨張性物質を有する複合材料の形成
US20020098553A1 (en) * 2001-01-19 2002-07-25 Pierre-Etienne Bost Process for producing carrageenan with reduced amount of insoluble material
CA2344910C (en) * 2001-04-23 2009-07-07 Kureha Chemical Industry Co., Ltd. Method for treating renal disease, and pharmaceutical composition for treating renal disease
EP1306128A1 (en) * 2001-10-29 2003-05-02 Tenaxis Gmbh Sorptive composite materials
JP4486300B2 (ja) 2002-07-25 2010-06-23 ユニ・チャーム株式会社 吸収性物品のトップシート
FR2843302B1 (fr) 2002-08-09 2004-10-22 Centre Nat Rech Scient Forme galenique pour la delivrance colique de principes actifs
JP3585043B2 (ja) * 2003-01-22 2004-11-04 メルク・ホエイ株式会社 医薬用吸着剤及びその製法
CA2523339A1 (en) * 2003-04-25 2004-11-11 Kouki Bussan Yugenkaisha Agent for preventing and healing constipation
GB2405343A (en) 2003-08-29 2005-03-02 Johnson & Johnson Medical Ltd Charcoal Wound Dressings
JP4409245B2 (ja) * 2003-10-20 2010-02-03 株式会社荏原製作所 耐食性及び耐摩耗性を有する被覆用合金を用いた装置
CN1615908B (zh) 2003-10-22 2011-09-28 株式会社吴羽 口服给药用吸附剂、以及肾病治疗或预防剂、和肝病治疗或预防剂
TWI370012B (en) * 2004-04-02 2012-08-11 Kureha Corp Adsorbent for oral administration, and agent for treating or preventing renal or liver disease
CA2569684C (en) 2004-06-07 2014-10-07 Kureha Corporation Dry composition for oral ingestion and gel composition prepared just before use for oral ingestion
EP1809259B1 (en) * 2004-10-15 2014-12-03 Supernus Pharmaceuticals, Inc. Less abusable pharmaceutical preparations
US9149439B2 (en) 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
BRPI0610683B8 (pt) 2005-05-18 2021-05-25 Hopitaux Paris Assist Publique aplicação colônica de absorventes
US20070243268A1 (en) * 2005-11-07 2007-10-18 Jaffe Russell M Compositions for regulating intestinal disorders and methods of use thereof
CA2632798A1 (en) 2005-12-06 2007-06-14 Ocera Therapeutics, Inc. Use of adsorbent carbon microspheres for the treatment of irritable bowel syndrome
US8557274B2 (en) * 2005-12-06 2013-10-15 Purdue Research Foundation Slowly digesting starch and fermentable fiber
DE102005062160A1 (de) * 2005-12-19 2007-06-21 BLüCHER GMBH Aktivkohle für die medizinische Verwendung
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
US20080089943A1 (en) * 2006-08-17 2008-04-17 Xavier Frapaise Use of adsorbent carbon microspheres to treat gastroesophogeal reflux disease
DE202006016898U1 (de) * 2006-10-12 2007-11-22 BLüCHER GMBH Hochleistungsadsorbentien auf der Basis von Aktivkohle mit hoher Mikroporosität
CA2678131A1 (en) * 2006-11-17 2008-05-22 Antoine Andremont Colonic delivery using zn/pectin beads with a eudragit coating.
WO2008073517A1 (en) * 2006-12-07 2008-06-19 Ehrenpreis Eli D Treatment for intestinal gas, bloating, microscopic colitis and traveler's diarrhea using colloidal bismuth subcitrate
WO2008084676A1 (ja) * 2006-12-26 2008-07-17 Medrx Co., Ltd. 多孔性乾燥マトリックスの医薬組成物
DE102007009242A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
US20090148538A1 (en) * 2007-10-12 2009-06-11 Ocera Therapeutics, Inc. Use of adsorbent carbon microspheres to treat pouchitis
DE102008014109A1 (de) 2008-03-13 2009-09-17 Bayer Animal Health Gmbh Suspensionsformulierung für Kohlenstoff-Adsorbentien
KR20100001892A (ko) 2008-06-27 2010-01-06 주식회사 에코비젼 핵입자를 함유하는 질산화 미생물의 그래뉼 및 질산화미생물의 그래뉼화 촉진방법
FR2950252B1 (fr) 2009-09-23 2012-01-20 Centre Nat Rech Scient Forme galenique capable d'adsorber de maniere specifique les molecules indesirables
PT2538930T (pt) * 2010-02-23 2016-08-05 Da Volterra Formulações para administração oral de adsorventes no intestino

Also Published As

Publication number Publication date
US20170296478A1 (en) 2017-10-19
BR112012021275A2 (pt) 2016-10-25
CN102869351A (zh) 2013-01-09
US11202761B2 (en) 2021-12-21
RU2016147198A (ru) 2018-06-01
US20180369156A1 (en) 2018-12-27
CA2790811C (en) 2017-12-05
PL2538930T3 (pl) 2016-11-30
ZA201207068B (en) 2013-05-29
EP2538930A1 (en) 2013-01-02
RS54991B1 (sr) 2016-11-30
CA2790811A1 (en) 2011-09-01
RU2012140421A (ru) 2014-03-27
LT2538930T (lt) 2016-09-26
CN102869351B (zh) 2015-07-01
JP5645975B2 (ja) 2014-12-24
US20220087945A1 (en) 2022-03-24
PT2538930T (pt) 2016-08-05
KR20130044214A (ko) 2013-05-02
EP2538930B1 (en) 2016-06-15
HRP20160834T1 (hr) 2016-09-23
IL221542A (en) 2017-06-29
US20130052269A1 (en) 2013-02-28
KR101820374B1 (ko) 2018-01-19
BR112012021275B1 (pt) 2021-07-27
RU2016147198A3 (el) 2018-06-01
HK1180233A1 (zh) 2013-10-18
HUE029299T2 (en) 2017-02-28
AU2011219788A1 (en) 2012-09-06
MX340822B (es) 2016-07-26
ES2586135T3 (es) 2016-10-11
JP2013520467A (ja) 2013-06-06
AU2011219788B2 (en) 2015-05-14
MX2012009728A (es) 2012-11-29
RU2681315C2 (ru) 2019-03-06
WO2011104275A1 (en) 2011-09-01
US10052288B2 (en) 2018-08-21
SI2538930T1 (sl) 2016-10-28
US9968562B2 (en) 2018-05-15

Similar Documents

Publication Publication Date Title
CY1117869T1 (el) Φαρμακοτεχνικες μορφες για απο του στοματος απελευθερωση προσροφητικων στο εντερο
CY1122628T1 (el) Χρηση αιθυλεστερα εικοσαπενταενοϊκου οξεος για θεραπεια υπερτριγλυκεριδαιμιας
CY1123549T1 (el) Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1124144T1 (el) Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CY1119167T1 (el) Αναστολεις toy nkcc για τη θεραπεια του αυτισμου
CY1124928T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
CY1121150T1 (el) Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας
CY1124298T1 (el) Φενφλουραμινη για χρηση στην θεραπευτικη αντιμετωπιση του συνδρομου dravet
CY1122480T1 (el) Μεθυλικη βαρδοξολονη για τη θεραπεια παχυσαρκιας
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
CY1120807T1 (el) Συνθεσεις και μεθοδοι για την τροποποιηση της smn2 συναρμογης σε ενα υποκειμενο
CY1122786T1 (el) Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης
CY1123051T1 (el) Ταπενταδολη για προληψη και θεραπεια καταθλιψης και αγχους
CY1115994T1 (el) Φαρμακευτικες τυποποιησεις οι οποιες περιεχουν προσδεματα υποδοχεα ντοπαμινης
CY1123999T1 (el) Φαρμακευτικη συνθεση που περιεχει νικοτινικο οξυ ή/και νικοτιναμιδιο ή/και τρυπτοφανη για να επηρεαστει θετικα η εντερικη μικροβιοκοινοτητα
CY1118680T1 (el) Φαρμακευτικη συνθεση
CY1121849T1 (el) Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1116264T1 (el) Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2
CY1116424T1 (el) Παραγωγο αδενινης ως αναστολεας ρι3κ
CY1115254T1 (el) Φαρμακευτικα διαλυματα, διαδικασιες για την παρασκευη τους και θεραπευτικες χρησεις
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
CY1113640T1 (el) Μεθοδοι για την θεραπευτικη αγωγη ρευματοειδους αρθριτιδας